Emerging infectious diseases
ISSN 1080-6040 · Centers for Disease Control and Prevention · United States · active 1935–2026
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Indexing & access
Access status: gold. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Emerging infectious diseases a predatory journal?
Our screening does not flag Emerging infectious diseases. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in DOAJ, Scopus, Web of Science, PubMed, which is a positive signal.
Is Emerging infectious diseases indexed in Scopus or Web of Science?
Per our venue index, Emerging infectious diseases appears in: DOAJ, Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is Emerging infectious diseases's impact?
Papers in Emerging infectious diseases are cited about 5.4 times each within two years of publication, and Scimago places it in Q1, with an h-index of 326. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.
Is Emerging infectious diseases open access?
Our index records its access status as "gold". Where this is derived from publisher-level signals rather than works-level data it is a heuristic, so confirm on the journal's own site — particularly if an article processing charge matters to you.
Similar venues
- MMWR Morbidity and Mortality Weekly ReportQ1 · Centers for Disease Control and Prevention
- Clinical Microbiology ReviewsQ1 · American Society for Microbiology
- The Lancet Infectious DiseasesQ1 · Elsevier BV
- Biotechnology AdvancesQ1 · Elsevier BV
- EurosurveillanceQ1 · European Centre for Disease Prevention and Control
- Current Opinion in Chemical EngineeringQ1 · Elsevier BV